반응식
C(OC(NC1C(=O)N2C(C)(C(O)=O)CCC2=NC=1)=O)C1C=CC=CC=1.C([O:30][C:31]([C:33]1([CH2:54][C:55]2[CH:60]=[CH:59][CH:58]=[CH:57][CH:56]=2)[N:37]2[C:38](=[O:53])[C:39]([NH:42][C:43]([O:45][CH2:46][C:47]3[CH:52]=[CH:51][CH:50]=[CH:49][CH:48]=3)=[O:44])=[CH:40][N:41]=[C:36]2[CH2:35][CH2:34]1)=[O:32])(C)(C)C>>[CH2:54]([C:33]1([C:31]([OH:32])=[O:30])[N:37]2[C:38](=[O:53])[C:39]([NH:42][C:43]([O:45][CH2:46][C:47]3[CH:52]=[CH:51][CH:50]=[CH:49][CH:48]=3)=[O:44])=[CH:40][N:41]=[C:36]2[CH2:35][CH2:34]1)[C:55]1[CH:56]=[CH:57][CH:58]=[CH:59][CH:60]=1참가 물질
3
반응물 2
생성물 1
실험 절차
According to the procedure for the preparation of intermediate 19b, intermediate 21a (149 mg, 0.313 mmol) was deproteted to afford 125 mg (95%) of intermediate 21b. MS (ESI) 420.4 (M+H+).
출처 및 근거
- ORD 기록
- ord-20c0265f8dc641c1a630eeba3226f3e7
- 출처 데이터셋
- uspto-grants-2006_08
- 특허 번호
- US07094783B2
연결된 노트
불러오는 중…